Novel Targeting Moiety and Payload Conjugates Summit Europe

Join us at the inaugural Novel Targeting Moiety and Payload Conjugate Summit Europe, the premier event for Europe's burgeoning novel drug conjugate market. With more companies than ever before utilising novel targeting moieties and novel payloads to widen the therapeutic index of their conjugate, this meeting will act as your gateway to explore how design approaches range from peptide-drug conjugates, bispecific-drug conjugates, antibody-oligonucleotide conjugates, radio-conjugates, and fragment drug conjugates.

Learn how alterations in the targeting moiety and payload can enhance target specificity and reduce off-target toxicity, improve tumour penetration in solid tumours, prevail over oligonucleotide delivery challenges, and improve PK properties to maximise efficacy and reduce toxicity.

Offering a platform for innovative biotechs to showcase how their technologies can address the challenges limiting the application of ADCs, this meeting will bring together a unique audience of C-level executives from European biotechs, Director through to Scientists from large pharma working on and exploring how to expand the conjugate design toolkit.

As the only event in Europe spotlighting novel conjugate approaches in a room of highly invested individuals; this event is novel by name and nature!

Don't miss out on shaping the future of targeted therapeutics in Europe!

URLs:
Tickets: https://go.evvnt.com/2495616-0?pid=10018
Website: https://go.evvnt.com/2495616-2?pid=10018
Brochure: https://go.evvnt.com/2495616-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: GBP 3597.00,
Drug Developer Pricing - Conference Only: GBP 2599.00,
Academic Pricing - Conference +Workshop Day: GBP 2997.00,
Academic Pricing - Conference Only: GBP 2199.00,
Service Provider Pricing - Conference Workshop Day: GBP 4297.00,
Service Provider Pricing - Conference Only: GBP 3099.00

Speakers: Ashley Taylor Associate Director, Chemistry, Manufacturing and Controls, Sutura Therapeutics, Chris-Carol Bremer, Chief Development Officer, Navigo Proteins, David Huang, Head of Medicinal Chemistry, OBI Pharma, David White, Senior Vice President and Head of Drug Discovery, ProteinQure Inc., Edwin Wagena, Chief Executive Officer, Sutura Therapeutics, Gokhan Yahioglu, Co-Founder and Director RandD Medicinal Chemistry, Antikor, Guitao Wang, President of Research and Development, Coherent Biopharma, Heidi Wang, Chief Executive Officer, OBI Pharma, Jose Munoz-Olaya, Chief Scientific Officer, Valink Therapeutics, Merle Fuchs, CEO, Managing Partner, PRAMOMOLECULAR GmbH, Miriam Bujny, Chief Development Officer, Sapreme Technologies BV, Nusrat Sanghamitra, Founder and Chief Executive Officer, CyGenica, Obinna Ubah, Principal Scientist and Programme Lead, Elasmogen Ltd, Setareh Shamsili, Chief Executive Officer and Chief Medical Officer, Coretag, Shu-Min Liu, Chief Executive Officer, Shenzhen Enduring Biotech, Ltd., Shyam Masrani, Principal, Medicxi, Stanley Lewis, Founder and Chief Executive Officer , A28 Therapeutics, Yuhong Xu, Chief Scientific Officer, Highfield Biopharmaceuticals